TY - JOUR
T1 - 1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancer.
AU - Cavaliere, Davide
AU - Cirocchi, Roberto
AU - Coccolini, Federico
AU - Fagotti, Anna
AU - Fambrini, Massimiliano
AU - Federici, Orietta
AU - Lorusso, Domenica
AU - Vaira, Marco
AU - Ceresoli, Marco
AU - Delrio, Paolo
AU - Garofalo, Alfredo
AU - Pignata, Sandro
AU - Scollo, Paolo
AU - Trojano, Vito
AU - Amadori, Andrea
AU - Ansaloni, Luca
AU - Cariti, Giuseppe
AU - De Cian, Franco
AU - De Iaco, Pierandrea
AU - De Simone, Michele
AU - Deraco, Marcello
AU - Donini, Annibale
AU - Fiorentini, Giammaria
AU - Frigerio, Luigi
AU - Greggi, Stefano
AU - Macri, Antonio
AU - Pasqual, Enrico Maria
AU - Roviello, Franco
AU - Sammartino, Paolo
AU - Sassaroli, Cinzia
AU - Scambia, Giovanni
AU - Staudacher, Carlo
AU - Vici, Patrizia
AU - Vizza, Enrico
AU - Valle, Mario
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Ovarian cancer (OC) remains relatively rare, although it is among the top 4 causes of cancer death for women younger than 50. The aggressive nature of the disease and its often late diagnosis with peritoneal involvement have an impact on prognosis. The current scientific literature presents ambiguous or uncertain indications for management of peritoneal carcinosis (PC) from OC, both owing to the lack of sufficient scientific data and their heterogeneity or lack of consistency. Therefore, the Italian Society of Surgical Oncology (SICO), the Italian Society of Obstetrics and Gynaecology, the Italian Association of Hospital Obstetricians and Gynaecologists, and the Italian Association of Medical Oncology conducted a multidisciplinary consensus conference (CC) on management of advanced OC presenting with PC during the SICO annual meeting in Naples, Italy, on September 10-11, 2015. An expert committee developed questions on diagnosis and staging work-up, indications, and procedural aspects for peritonectomy, systemic chemotherapy, and hyperthermic intraperitoneal chemotherapy for PC from OC. These questions were provided to 6 invited speakers who answered with an evidence-based report. Each report was submitted to a jury panel, representative of Italian experts in the fields of surgical oncology, gynecology, and medical oncology. The jury panel revised the reports before and after the open discussion during the CC. This article is the final document containing the clinical evidence reports and statements, revised and approved by all the authors before submission.
AB - Ovarian cancer (OC) remains relatively rare, although it is among the top 4 causes of cancer death for women younger than 50. The aggressive nature of the disease and its often late diagnosis with peritoneal involvement have an impact on prognosis. The current scientific literature presents ambiguous or uncertain indications for management of peritoneal carcinosis (PC) from OC, both owing to the lack of sufficient scientific data and their heterogeneity or lack of consistency. Therefore, the Italian Society of Surgical Oncology (SICO), the Italian Society of Obstetrics and Gynaecology, the Italian Association of Hospital Obstetricians and Gynaecologists, and the Italian Association of Medical Oncology conducted a multidisciplinary consensus conference (CC) on management of advanced OC presenting with PC during the SICO annual meeting in Naples, Italy, on September 10-11, 2015. An expert committee developed questions on diagnosis and staging work-up, indications, and procedural aspects for peritonectomy, systemic chemotherapy, and hyperthermic intraperitoneal chemotherapy for PC from OC. These questions were provided to 6 invited speakers who answered with an evidence-based report. Each report was submitted to a jury panel, representative of Italian experts in the fields of surgical oncology, gynecology, and medical oncology. The jury panel revised the reports before and after the open discussion during the CC. This article is the final document containing the clinical evidence reports and statements, revised and approved by all the authors before submission.
KW - Combined Modality Therapy, Cytoreduction Surgical Procedures/methods, Evidence-Based Medicine, Female, Gynecologic Surgical Procedures/methods, Humans, Hyperthermia, Induced/methods, Italy, Ovarian Neoplasms/diagnosis/therapy, Peritoneal Neoplasms/diagnos
M3 - Article
SN - 0300-8916
VL - 103
SP - 525
EP - 536
JO - Tumori
JF - Tumori
ER -